MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.

Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi will advance the development of AlphaMedix along with RadioMedix and Orano Med. Credit: ArDanMe/Shutterstock. Sanofi has signed an exclusive licensing agreement with RadioMedix and

September 13, 2024

Cannabis Stocks – TCNNF stock analysis looking at TCNNF stock with value investing principles

September 22, 2023

Wane in Covid demand hurts Walgreens as profits drop to $118m – Pharmaceutical Technology

Shares in Walgreens dipped around 9% following the mixed Q3 results. Image credit: Shutterstock/P. Allison Walgreens Boots Alliance has set its sights on a cost-saving

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.